Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Journal of Gastroenterology
Published in: Clinical Journal of Gastroenterology 3/2014

Open Access 01-06-2014 | Clinical Review

Diagnosis and management of intestinal Behçet’s disease

Authors: Tadakazu Hisamatsu, Makoto Naganuma, Katsuyoshi Matsuoka, Takanori Kanai

Published in: Clinical Journal of Gastroenterology | Issue 3/2014

Login to get access

Abstract

Behçet’s disease (BD) is a chronic relapsing disease with multiple organ system involvement characterized clinically by oral and genital aphthae, cutaneous lesions, and ophthalmological, neurological, and/or gastrointestinal manifestations. Little clinical evidence is available regarding the management of patients with intestinal BD, despite recognition that the presence of intestinal lesions is a poor prognostic factor, causing perforation and massive bleeding. Many recent case reports have suggested that anti-tumor necrosis factor alpha (TNF)α monoclonal antibodies (mAbs) are effective in patients with intestinal BD. Adalimumab, a fully human anti-TNFα mAb, has been approved in Japan for the treatment of intestinal BD. Here, we review the pathogenesis, diagnosis and management of intestinal BD, including evidence of the efficacy of anti-TNFα mAbs.
Literature
1.
Behçet H. Uber rezidivierende, aphthose, durch ein Virus verursachte Geschwire am Mund, am Auge und an den Genitalen. Dermatol Wochenschr. 1937;105:1152–7.
2.
Garton RA, Ghate JV, Jorizzo JL. Behçet’s disease. In: Harris Jr ED, Budd RC, Genovese MC, Firestein GS, Sargent JS, Sledge CB, editors. Textbook of rheumatology. 7th ed. Philadelphia: Saunders; 2005.
3.
4.
Criteria for diagnosis of Behçet’s disease. International study group for Behçet’s disease. Lancet. 1990;335:1078–80.
5.
6.
7.
Tursen U, Gurler A, Boyvat A. Evaluation of clinical findings according to sex in 2313 Turkish patients with Behçet’s disease. Int J Dermatol. 2003;42:346–51.PubMedCrossRef
8.
Brandt LJ, Boley SJ. Intestinal ischemia. In: Feldman M, Friedman LS, Sleisenger MH, editors. Gastrointestinal and liver disease. 7th ed. Philadelphia: Saunders; 2002.
9.
Kobayashi K, Ueno F, Bito S, Iwao Y, Fukushima T, Hiwatashi N, et al. Development of consensus statements for the diagnosis and management of intestinal Behçet’s disease using a modified Delphi approach. J Gastroenterol. 2007;42:737–45.PubMedCrossRef
10.
Muto T. Iwayuru “simple ulcer” towa. (Historical review of so called “simple ulcer” of the intestine.) I to Chou. (Stomach Intestine.) 1979;14:739–48. (in Japanese).
11.
Hayasaki N, Ito M, Suzuki T, Ina K, Ando T, Kusugami K, et al. Neutrophilic phlebitis is characteristic of intestinal Behçet’s disease and simple ulcer syndrome. Histopathology. 2004;45:377–83.PubMedCrossRef
12.
Cheon JH, Kim ES, Shin SJ, Kim TI, Lee KM, Kim SW, et al. Development and validation of novel diagnostic criteria for intestinal Behçet’s disease in Korean patients with ileocolonic ulcers. Am J Gastroenterol. 2009;104:2492–9.PubMedCrossRef
13.
Lorenzetti ME, Forbes IJ, Roberts-Thomson IC. Oesophageal and ileal ulceration in Behçet’s disease. J Gastroenterol Hepatol. 1990;5:714–7.PubMedCrossRef
14.
Ikezawa K, Kashimura H, Hassan M, Nakahara A, Yanaka A, Matsuzaki Y, et al. A case of Behçet’s syndrome with esophageal involvement treated with salicylazosulfapyridine and prednisolone. Endoscopy. 1998;30:S52–3.PubMedCrossRef
15.
Yasuo M, Miyabayashi H, Okano T, Aoki H, Ichikawa K, Hirose Y. Successful treatment with corticosteroid in a case of Behçet’s syndrome with multiple esophageal ulcerations. Intern Med. 2003;42:696–9.PubMedCrossRef
16.
Yokota K, Hirano M, Akiba H, Adachi D, Takeishi M, Akiyama Y, et al. A case of Behçet’s disease with esophageal ulcers complicated with systemic sclerosis, chronic hepatitis C, and pancytopenia. Nihon Rinsho Meneki Gakkai Kaishi. 2004;27:164–70.PubMedCrossRef
17.
Fujiwara S, Shimizu I, Ishikawa M, Uehara K, Yamamoto H, Okazaki M, et al. Intestinal Behcet’s disease with esophageal ulcers and colonic longitudinal ulcers. World J Gastroenterol. 2006;12:2622–4.PubMed
18.
Bottomley WW, Dakkak M, Walton S, Bennett JR. Esophageal involvement in Behçet’s disease. Is endoscopy necessary? Dig Dis Sci. 1992;37:594–7.PubMedCrossRef
19.
Yi SW, Cheon JH, Kim JH, Lee SK, Kim TI, Lee YC, et al. The prevalence and clinical characteristics of esophageal involvement in patients with Behçet’s disease: a single center experience in Korea. J Korean Med Sci. 2009;24:52–6.PubMedCentralPubMedCrossRef
20.
Chang DK, Kim JJ, Choi H, Eun CS, Han DS, Byeon JS, et al. Double balloon endoscopy in small intestinal Crohn’s disease and other inflammatory diseases such as cryptogenic multifocal ulcerous stenosing enteritis (CMUSE). Gastrointest Endosc. 2007;66:S96–8.PubMedCrossRef
21.
Gubler C, Bauerfeind P. Intestinal Behçet’s disease diagnosed by capsule endoscopy. Endoscopy. 2005;37:689.PubMedCrossRef
22.
Hamdulay SS, Cheent K, Ghosh C, Stocks J, Ghosh S, Haskard DO. Wireless capsule endoscopy in the investigation of intestinal Behçet’s syndrome. Rheumatology (Oxford). 2008;47:1231–4.CrossRef
23.
Neves FS, Fylyk SN, Lage LV, Ishioka S, Goldenstein-Schainberg C, Sakai P, et al. Behçet’s disease: clinical value of the video capsule endoscopy for small intestine examination. Rheumatol Int. 2009;29:601–3.PubMedCrossRef
24.
Chong VF, Pathmanathan R. Familial Behçet’s syndrome with intestinal involvement—case reports and a review of the literature. Ann Acad Med Singapore. 1993;22:807–10.PubMed
25.
Kobayashi T, Sudo Y, Okamura S, Ohashi S, Urano F, Hosoi T, et al. Monozygotic twins concordant for intestinal Behçet’s disease. J Gastroenterol. 2005;40:421–5.PubMedCrossRef
26.
Mizuki N, Meguro A, Ota M, Ohno S, Shiota T, Kawagoe T, et al. Genome-wide association studies identify IL23R–IL12RB2 and IL10 as Behçet’s disease susceptibility loci. Nat Genet. 2010;42:703–6.PubMedCrossRef
27.
Remmers EF, Cosan F, Kirino Y, Ombrello MJ, Abaci N, Satorius C, et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet’s disease. Nat Genet. 2010;42:698–702.PubMedCentralPubMedCrossRef
28.
Lee YJ, Horie Y, Wallace GR, Choi YS, Park JA, Choi JY, et al. Genome-wide association study identifies GIMAP as a novel susceptibility locus for Behcet’s disease. Ann Rheum Dis. 2013;72:1510–6.PubMedCrossRef
29.
Hou S, Yang Z, Du L, Jiang Z, Shu Q, Chen Y, et al. Identification of a susceptibility locus in STAT4 for Behçet’s disease in Han Chinese in a genome-wide association study. Arthr Rheum. 2012;64:4104–13.CrossRef
30.
Ahn JK, Cha HS, Lee J, Jeon CH, Koh EM. Correlation of DEFA1 gene copy number variation with intestinal involvement in Behcet’s disease. J Korean Med Sci. 2012;27:107–9.PubMedCentralPubMedCrossRef
31.
Takada H, Nomura A, Ishimura M, Ichiyama M, Ohga S, Hara T. NEMO mutation as a cause of familial occurrence of Behçet’s disease in female patients. Clin Genet. 2010;78:575–9.PubMedCrossRef
32.
Nara K, Kurokawa MS, Chiba S, Yoshikawa H, Tsukikawa S, Matsuda T, et al. Involvement of innate immunity in the pathogenesis of intestinal Behçet’s disease. Clin Exp Immunol. 2008;152:245–51.PubMedCentralPubMedCrossRef
33.
Imamura Y, Kurokawa MS, Yoshikawa H, Nara K, Takada E, Masuda C, et al. Involvement of Th1 cells and heat shock protein 60 in the pathogenesis of intestinal Behcet’s disease. Clin Exp Immunol. 2005;139:371–8.PubMedCentralPubMedCrossRef
34.
Ferrante A, Ciccia F, Principato A, Giardina AR, Impastato R, Peralta S, et al. A Th1 but not a Th17 response is present in the gastrointestinal involvement of Behçet’s disease. Clin Exp Rheumatol. 2010;28:S27–30.PubMed
35.
Tada Y, Koarada S, Haruta Y, Mitamura M, Ohta A, Nagasawa K. The association of Behçet’s disease with myelodysplastic syndrome in Japan: a review of the literature. Clin Exp Rheumatol. 2006;24:S115–9.PubMed
36.
Ahn JK, Cha HS, Koh EM, Kim SH, Kim YG, Lee CK, et al. Behcet’s disease associated with bone marrow failure in Korean patients: clinical characteristics and the association of intestinal ulceration and trisomy 8. Rheumatology (Oxford). 2008;47:1228–30.CrossRef
37.
Kimura S, Kuroda J, Akaogi T, Hayashi H, Kobayashi Y, Kondo M. Trisomy 8 involved in myelodysplastic syndromes as a risk factor for intestinal ulcers and thrombosis—Behçet’s syndrome. Leuk Lymphoma. 2001;42:115–21.PubMedCrossRef
38.
Voulgarelis M, Giannouli S, Ritis K, Tzioufas AG. Myelodysplasia-associated autoimmunity: clinical and pathophysiologic concepts. Eur J Clin Invest. 2004;34:690–700.PubMedCrossRef
39.
Hsu HC, Lee YM, Tsai WH, Jiang ML, Ho CH, Ho CK, et al. Circulating levels of thrombopoietic and inflammatory cytokines in patients with acute myeloblastic leukemia and myelodysplastic syndrome. Oncology. 2002;63:64–9.PubMedCrossRef
40.
Zeng W, Chen G, Kajigaya S, Nunez O, Charrow A, Billings EM, et al. Gene expression profiling in CD34 cells to identify differences between aplastic anemia patients and healthy volunteers. Blood. 2004;103:325–32.PubMedCrossRef
41.
Fellermann K, Stange DE, Schaeffeler E, Schmalzl H, Wehkamp J, Bevins CL, et al. A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colon. Am J Hum Genet. 2006;79:439–48.PubMedCentralPubMedCrossRef
42.
Tanaka H, Shimizu N, Tougasaki E, Kawajiri C, Hashimoto S, Takeda Y, et al. Successful treatment by azacitidine therapy of intestinal Behçet’s disease associated with myelodysplastic syndrome. Int J Hematol. 2013;97:520–4.PubMedCrossRef
43.
Jung YS, Hong SP, Kim TI, Kim WH, Cheon JH. Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with intestinal Behçet disease. J Clin Gastroenterol. 2012;46:e38–45.PubMedCrossRef
44.
Sonta T, Araki Y, Koubokawa M, Tamura Y, Ochiai T, Harada N, et al. The beneficial effect of mesalazine on esophageal ulcers in intestinal Behcet’s disease. J Clin Gastroenterol. 2000;30:195–9.PubMedCrossRef
45.
Nakase H, Okazaki K, Kawanami C, Uchida K, Ohana M, Uose S, et al. Therapeutic effects on intestinal Behçet’s disease of an intravenous drug delivery system using dexamethasone incorporated in lipid emulsion. J Gastroenterol Hepatol. 2001;16:1306–8.PubMedCrossRef
46.
Toda K, Shiratori Y, Yasuda M, Enya M, Uematsu T, Shimazaki M, et al. Therapeutic effect of intraarterial prednisolone injection in severe intestinal Behçet’s disease. J Gastroenterol. 2002;37:844–8.PubMedCrossRef
47.
Takada Y, Saigenji K. Is intestinal Behçet’s disease in fact an enterocolitis or an ulcer disease, and is steroid treatment useful or harmful? J Gastroenterol. 2003;38:1015–6.PubMedCrossRef
48.
Jung YS, Cheon JH, Hong SP, Kim TI, Kim WH. Clinical outcomes and prognostic factors for thiopurine maintenance therapy in patients with intestinal Behcet’s disease. Inflamm Bowel Dis. 2012;18:750–7.PubMedCrossRef
49.
Iwata S, Saito K, Yamaoka K, Tsujimura S, Nawata M, Hanami K, et al. Efficacy of combination therapy of anti-TNF-α antibody infliximab and methotrexate in refractory entero-Behçet’s disease. Mod Rheumatol. 2011;21:184–91.PubMedCrossRef
50.
Matsumura K, Nakase H, Chiba T. Efficacy of oral tacrolimus on intestinal Behcet’s disease. Inflamm Bowel Dis. 2010;16:188–9.PubMedCrossRef
51.
Yasui K, Uchida N, Akazawa Y, Nakamura S, Minami I, Amano Y, et al. Thalidomide for treatment of intestinal involvement of juvenile-onset Behçet disease. Inflamm Bowel Dis. 2008;14:396–400.PubMedCrossRef
52.
Sayarlioglu M, Kotan MC, Topcu N, Bayram I, Arslanturk H, Gul A. Treatment of recurrent perforating intestinal ulcers with thalidomide in Behçet’s disease. Ann Pharmacother. 2004;38:808–11.PubMedCrossRef
53.
Travis SP, Czajkowski M, McGovern DP, Watson RG, Bell AL. Treatment of intestinal Behçet’s syndrome with chimeric tumour necrosis factor alpha antibody. Gut. 2001;49:725–8.PubMedCentralPubMedCrossRef
54.
Naganuma M, Iwao Y, Inoue N, Hisamatsu T, Imaeda H, Ishii H, et al. Analysis of clinical course and long-term prognosis of surgical and nonsurgical patients with intestinal Behçet’s disease. Am J Gastroenterol. 2000;95:2848–51.PubMed
55.
Iida M, Kobayashi H, Matsumoto T, Okada M, Fuchigami T, Yao T, et al. Postoperative recurrence in patients with intestinal Behçet’s disease. Dis Colon Rectum. 1994;37:16–21.PubMedCrossRef
56.
Jung YS, Yoon JY, Lee JH, Jeon SM, Hong SP, Kim TI, et al. Prognostic factors and long-term clinical outcomes for surgical patients with intestinal Behcet’s disease. Inflamm Bowel Dis. 2011;17:1594–602.PubMedCrossRef
57.
Jung YS, Cheon JH, Park SJ, Hong SP, Kim TI, Kim WH. Clinical course of intestinal Behcet’s disease during the first five years. Dig Dis Sci. 2013;58:496–503.PubMedCrossRef
58.
Hassard PV, Binder SW, Nelson V, Vasiliauskas EA. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet’s disease: a case report. Gastroenterology. 2001;120:995–9.PubMedCrossRef
59.
Kram MT, May LD, Goodman S, Molinas S. Behçet’s ileocolitis: successful treatment with tumor necrosis factor-alpha antibody (infliximab) therapy: report of a case. Dis Colon Rectum. 2003;46:118–21.PubMedCrossRef
60.
Lee JH, Kim TN, Choi ST, Jang BI, Shin KC, Lee SB, et al. Remission of intestinal Behçet’s disease treated with anti-tumor necrosis factor alpha monoclonal antibody (infliximab). Korean J Intern Med. 2007;22:24–7.PubMedCentralPubMedCrossRef
61.
Naganuma M, Sakuraba A, Hisamatsu T, Ochiai H, Hasegawa H, Ogata H, et al. Efficacy of infliximab for induction and maintenance of remission in intestinal Behçet’s disease. Inflamm Bowel Dis. 2008;14:1259–64.PubMedCrossRef
62.
Lee JH, Cheon JH, Jeon SW, Ye BD, Yang SK, Kim YH, et al. Efficacy of infliximab in intestinal Behçet’s disease: a Korean multicenter retrospective study. Inflamm Bowel Dis. 2013;19:1833–8.PubMed
63.
Byeon JS, Choi EK, Heo NY, Hong SC, Myung SJ, Yang SK, et al. Antitumor necrosis factor-alpha therapy for early postoperative recurrence of gastrointestinal Behçet’s disease: report of a case. Dis Colon Rectum. 2007;50:672–6.PubMedCrossRef
64.
Saulsbury FT, Mann JA. Treatment with infliximab for a child with Behçet’s disease. Arthr Rheum. 2003;49:599–600.CrossRef
65.
Ugras M, Ertem D, Celikel C, Pehlivanoglu E. Infliximab as an alternative treatment for Behçet disease when other therapies fail. J Pediatr Gastroenterol Nutr. 2008;46:212–5.PubMedCrossRef
66.
Ariyachaipanich A, Berkelhammer C, Nicola H. Intestinal Behçet’s disease: maintenance of remission with adalimumab monotherapy. Inflamm Bowel Dis. 2009;15:1769–71.PubMedCrossRef
67.
Chung SH, Park SJ, Hong SP, Cheon JH, Kim TI, Kim WH. Intestinal Behçet’s disease appearing during treatment with adalimumab in a patient with ankylosing spondylitis. World J Gastroenterol. 2013;19:5389–92.PubMedCentralPubMedCrossRef
68.
Hisamatsu T, Ueno F, Matsumoto T, Kobayashi K, Koganei K, Kunisaki R, et al. The 2nd edition of consensus statements for the diagnosis and management of intestinal Behçet’s disease: indication of anti-TNFα monoclonal antibodies. J Gastroenterol. 2014;49:156–62.PubMedCentralPubMedCrossRef
69.
Pariente B, Cosnes J, Danese S, Sandborn WJ, Lewin M, Fletcher JG, et al. Development of the Crohn’s disease digestive damage score, the Lémann score. Inflamm Bowel Dis. 2011;17:1415–22.PubMedCentralPubMedCrossRef
70.
Kaburaki T, Namba K, Sonoda KH, Kezuka T, Keino H, Fukuhara T, Ocular Behçet Disease Research Group of Japan, et al. Behçet’s disease ocular attack score 24: evaluation of ocular disease activity before and after initiation of infliximab. Jpn J Ophthalmol. 2014;58:120–30.PubMedCrossRef
71.
Zallot C, Peyrin-Biroulet L. Deep remission in inflammatory bowel disease: looking beyond symptoms. Curr Gastroenterol Rep. 2013;15:315.PubMedCrossRef
72.
Maruyama Y, Hisamatsu T, Matsuoka K, Naganuma M, Inoue N, Ogata H, et al. A case of intestinal Behçet’s disease treated with infliximab monotherapy who successfully maintained clinical remission and complete mucosal healing for six years. Intern Med. 2012;51:2125–9.PubMedCrossRef
73.
Lee HJ, Kim YN, Jang HW, Jeon HH, Jung ES, Park SJ, et al. Correlations between endoscopic and clinical disease activity indices in intestinal Behcet’s disease. World J Gastroenterol. 2012;18:5771–8.PubMedCentralPubMedCrossRef
74.
Schreiber S, Reinisch W, Colombel JF, Sandborn WJ, Hommes DW, Robinson AM, et al. Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn’s disease. J Crohns Colitis. 2013;7:213–21.PubMedCrossRef
75.
Van Assche G, Magdelaine-Beuzelin C, D’Haens G, Baert F, Noman M, Vermeire S, et al. Withdrawal of immunosuppression in Crohn’s disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology. 2008;134:1861–8.PubMedCrossRef
76.
Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, Van Assche G, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort. Gut. 2009;58:492–500.PubMedCrossRef
77.
Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, SONIC Study Group, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362:1383–95.PubMedCrossRef
78.
Dassopoulos T, Sultan S, Falck-Ytter YT, Inadomi JM, Hanauer SB. American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn’s disease. Gastroenterology. 2013;145:1464–78.PubMedCrossRef
Metadata
Title
Diagnosis and management of intestinal Behçet’s disease
Authors
Tadakazu Hisamatsu
Makoto Naganuma
Katsuyoshi Matsuoka
Takanori Kanai
Publication date
01-06-2014
Publisher
Springer Japan
Published in
Clinical Journal of Gastroenterology / Issue 3/2014
Print ISSN: 1865-7257
Electronic ISSN: 1865-7265
DOI
https://doi.org/10.1007/s12328-014-0488-0

Other articles of this Issue 3/2014

Clinical Journal of Gastroenterology 3/2014 Go to the issue

Case Report

Endoscopic submucosal dissection of a squamous cell carcinoma in situ in the anal canal diagnosed by magnifying endoscopy with narrow-band imaging

Clinical Review

Advances in balloon endoscopes

Case Report

A male patient with ferroportin disease B and a female patient with iron overload similar to ferroportin disease B

Case Report

A case of severe pseudomembranous colitis diagnosed by colonoscopy after Helicobacter pylori eradication

Case Report

Middle-preserving pancreatectomy for multifocal intraductal papillary mucinous neoplasms of the pancreas: report of a case

Case Report

Long-term survival after resection of brain metastases from esophagogastric junction adenocarcinoma: report of two cases and review of the literature
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits